X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Urolithiasis

期刊標題檢索 UROLITHIASIS 最新評論: Hello senior, I would like to ask if after submitting in the system, d... (2023-10-13)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Urolithiasis]您好,您是該頁面的第 16993 位訪客。

期刊簡介
期刊名稱Urolithiasis Urolithiasis
LetPub Score
5.1
50 ratings
Rate

Reputation
6.3

Influence
3.9

Speed
7.0

期刊簡稱UROLITHIASIS
ISSN2194-7228
E-ISSN2194-7236
h-index55
CiteScore
CiteScoreSJRSNIPCiteScore Rank
4.500.8031.181
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Urology
Q233 / 120

自引率 (2023-2024)10.00%自引率趨勢
掲載範囲
Official Journal of the International Urolithiasis Society

The journal aims to publish original articles in the fields of clinical and experimental investigation only within the sphere of urolithiasis and its related areas of research. The journal covers all aspects of urolithiasis research including the diagnosis, epidemiology, pathogenesis, genetics, clinical biochemistry, open and non-invasive surgical intervention, nephrological investigation, chemistry and prophylaxis of the disorder. The Editor welcomes contributions on topics of interest to urologists, nephrologists, radiologists, clinical biochemists, epidemiologists, nutritionists, basic scientists and nurses working in that field.

Contributions may be submitted as full-length articles or as rapid communications in the form of Letters to the Editor. Articles should be original and should contain important new findings from carefully conducted studies designed to produce statistically significant data. Please note that we no longer publish articles classified as Case Reports. Editorials and review articles may be published by invitation from the Editorial Board. All submissions are peer-reviewed. Through an electronic system for the submission and review of manuscripts, the Editor and Associate Editors aim to make publication accessible as quickly as possible to a large number of readers throughout the world.
官方網站https://www.springer.com/240
在線稿件提交https://www.editorialmanager.com/ures
開放訪問No
出版商Springer Berlin Heidelberg
主題領域UROLOGY & NEPHROLOGY
出版國/地區UNITED STATES
發行頻率年6回刊行
創刊年1973
每年文章數98每年文章數趨勢
黃金OA百分比22.49%
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
UROLOGY & NEPHROLOGYSCIEQ261/126
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2194-7228%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據:
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Urolithiasis】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 137.40
    LANCETH-index: 700

    CiteScore: 148.10
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 145.40
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 76.70
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 48.20
    World PsychiatryH-index: 70

    CiteScore: 64.10
    學科內最受檢索的期刊 頁面查看次數
    MEDICINE645705
    BIOMATERIALS600889
    Frontiers in Pharmacology502685
    BIOMEDICINE & PHARMACOTHERAPY498656
    JOURNAL OF ETHNOPHARMACOLOGY494663
    Journal of Materials Chemistry B476181
    Frontiers in Immunology461411
    COMPUTERS IN BIOLOGY AND MEDICINE420230
    COLLOIDS AND SURFACES B-BIOINTERFACES419538
    Frontiers in Oncology415875
  •  

    Urolithiasis Urolithiasis
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [Urolithiasis] 的評論撰寫評論
作者: 坠星红毅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-13 16:09:18 評論於
Hello senior, I would like to ask if after submitting in the system, do I need to resubmit in the link in the email? I received an email saying the submission was incomplete, and the link in it led me to resubmit
(0) 讚! | 坠星红毅

作者: 震雷舒婕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-19 13:23:52 評論於
So what is the result?
(0) 讚! | 震雷舒婕

作者: 震雷舒婕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-11 13:01:51 評論於
It's been almost two months since it was sent back for repairs, but there's still no news
(0) 讚! | 震雷舒婕

作者: 震雷舒婕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-21 23:30:38 評論於
I have been here for a month
(0) 讚! | 震雷舒婕

作者: 是你的乐琴呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-26 16:02:21 評論於
After receiving the revisions, it took almost a week to make the necessary changes and send them back
(0) 讚! | 是你的乐琴呀

作者: 是你的乐琴呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-01-24 08:40:53 評論於
On 12.29 became 1 reviewer received, and then no change
(0) 讚! | 是你的乐琴呀

作者: 奉天可馨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-16 22:21:38 評論於
How is this article, have you received it?
(0) 讚! | 奉天可馨

作者: 是你的乐琴呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-14 22:00:53 評論於
Editor has been appointed for 18 days and there is still no change. Does anyone know what's going on
(0) 讚! | 是你的乐琴呀

作者: 苍风凝梅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-18 12:05:01 評論於
Thank you so much!
(0) 讚! | 苍风凝梅

作者: 岱宗田然


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-17 14:13:56 評論於
You can send an email to sandra.lesny@springer.com to urge them. This person is more responsive. The other email on the official website is unlikely to reply, or the replies are just generic responses
(0) 讚! | 岱宗田然

作者: 岱宗田然


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-17 12:55:12 評論於
I waited for two months without finding a reviewer, so I withdrew the submission... I used to think this journal was pretty fast, with results in about a month, but now I can't find any reviewers
(0) 讚! | 岱宗田然

作者: 苍风凝梅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-15 19:16:08 評論於
Review speed: 6.0 | Submission success rate: 25.0
Experience sharing: I submitted my paper on September 16th, and it was displayed in the invitation of experts on October 1st. It is now November 15th, but there has been no changes on the page and I have not received any emails or messages. I am really anxious as I am about to graduate. Can anyone please tell me what is going on and what should I do?
(0) 讚! | 苍风凝梅

作者: 苍风凝梅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-15 17:56:10 評論於
I also want to ask, it has been two months since submitting the paper, and still 5 reviewers invited, I don't know what the situation is
(0) 讚! | 苍风凝梅

作者: 苍风凝梅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-15 12:17:41 評論於
How is the situation going? Please let me know
(0) 讚! | 苍风凝梅

作者: 岱宗田然


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-05-15 16:40:59 評論於
I have submitted my paper through Springer's new system a month ago, and I have received invitations from 4 reviewers. Will it show as "under review" status?
(0) 讚! | 岱宗田然

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 18:43:35 評論於
The method of relative quantification in qPCR is the ΔΔCT method, which first calibrates with reference genes, and then calculates the difference between samples and control groups
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 09:13:31 評論於
Calculate the average value (Mean) using Average(), the standard deviation (SD) using STDEV.S(), and the standard error (SEM) using STDEV.S()/COUNT()^0.5
(0) 讚! | 维尔娜菲茨杰拉德

作者: 魂魄彦露


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 11:26:56 評論於
How to calculate the margin of error?
(0) 讚! | 魂魄彦露

作者: 龙鳞孝礼


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 08:44:22 評論於
How to handle the results of qPCR?
(0) 讚! | 龙鳞孝礼

作者: 多罗涵博


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-08-29 21:38:38 評論於
Review speed: 1.0 | Submission acceptance rate: 50.0
Main research direction: experience sharing of urinary stones
Comments: The first submission was rejected, it took 1 week, and a lot of feedback was provided. After revising based on the feedback, it was accepted. The whole process took about 2 months. The editor was very responsible. Thumbs up
(0) 讚! | 多罗涵博

作者: Oliver Jerry


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-10-25 18:20:31 評論於
Awesome
(0) 讚! | Oliver Jerry

作者: 云来之南


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-03-26 17:45:45 評論於
IF1.816
Hardy-Tau 2018-03-26 published:: Acceptance rate: about 50% Review time: about 1 month for first review, one month for major revisions. However, not many major revisions needed. Total of two reviewers. Made revisions based on reviewers' comments. Accepted in mid-March. Article is published by Springer. No publication fee required. Now available online
(0) 讚! | 云来之南

作者: 云来之南


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-03-26 17:30:47 評論於
Review Speed: 1.0 | Acceptance Rate: 50.0
Experience Sharing: One month notice for major revisions after the first review. However, there are not many comments. There are a total of two reviewers. Make revisions based on the comments of the reviewers. Accepted in mid-March. The article is published by Springer. No page charges. The article is now online
(0) 讚! | 云来之南

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-14 14:14:44 評論於
From below 1.5 points, it is now approaching 2 points, which is a good sign. This magazine is worth having
(0) 讚! | 凌霄高洁

作者: 碧桃小之


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-03-16 13:50:44 評論於
Is this article about accepting kidney disease? Posted on 2014-08-11 :: Research direction: urolithiasis;; Acceptance rate: about 50% Review time: about 2 months Ah! This year it has actually decreased, the editors and reviewers feel good, the review speed is also relatively fast, no need to pay~
(0) 讚! | 碧桃小之

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [Urolithiasis] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*